The Impact of Weight Loss Programs on BMI Trajectory in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Veterans Health Administration Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38534167.
- Also identified by DOI 10.14309/ajg.0000000000002785 and PMC identifier 12036740.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Weight loss is the mainstay of management for patients with metabolic dysfunction-associated steatotic liver disease. We studied the impact of referral to MOVE!, a nationally-implemented behavioral weight loss program, on weight in MASLD patients. This retrospective cohort study included 102,294 MASLD patients from 125 Veterans Health Administration centers from 2008-2022. Most patients lost no significant weight or gained weight. Increased engagement with MOVE! was associated with greater hazard of significant weight loss compared to no engagement. A minority of patients experienced significant weight loss through 5 years using lifestyle interventions alone.